Volume 58, Issue 1, Pages (July 2000)

Slides:

Advertisements

Similar presentations

Volume 376, Issue 9734, Pages (July 2010)

Advertisements

Intensive hemodialysis—keeping the faith

Volume 376, Issue 9734, Pages (July 2010)

Lipopheresis in the nephrotic syndrome

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Volume 87, Issue 1, Pages (January 2015)

Intensive hemodialysis—keeping the faith

Volume 77, Issue 1, Pages 6-8 (January 2010)

Volume 58, Issue 1, Pages (July 2000)

Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real? S. Andrulli, S. Di Filippo, F. Locatelli

Jeffrey C. Fink, Glenn M. Chertow Kidney International

Peripheral microvascular parameters in the nephrotic syndrome

Volume 87, Issue 1, Pages (January 2015)

Volume 65, Issue 1, Pages (January 2004)

Volume 92, Issue 1, Pages (July 2017)

Volume 86, Issue 1, Pages (July 2014)

Volume 70, Issue 11, Pages (December 2006)

Edmund G. Lowrie Kidney International

U-shaped effect of eGFR and mortality

Volume 87, Issue 1, Pages (January 2015)

Unfavorable course of minimal change nephrotic syndrome in children with intrauterine growth retardation Nina Zidar, Mojca Avguštin Čavić, Rajko B. Kenda,

Volume 70, Issue 12, Pages (December 2006)

Volume 73, Issue 10, Pages (May 2008)

Prescribing and monitoring hemodialysis dose

Volume 61, Issue 4, Pages (April 2002)

Fructose intake as a risk factor for kidney stone disease

Volume 73, Issue 12, Pages (June 2008)

Peritoneal dialysis adequacy and risk of death

Volume 87, Issue 1, Pages (January 2015)

A physician's perseverance uncovers problems in a key nephrology study

Volume 72, Issue 1, Pages 8-10 (July 2007)

Volume 72, Issue 12, Pages (December 2007)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Abdulla K. Salahudeen, Erwin H. Fleischmann, John D. Bower

Alternate-day dialysis may be needed for hemodialysis patients

Methods for guideline development

Racial disparities in access to transplantation: a tough nut to crack

Simvastatin in nephrotic syndrome

Nephrology Crossword: Glomerulonephritis

Michael W. Steffes, Derek Schmidt, Rebecca Mccrery, John M. Basgen

Volume 71, Issue 4, Pages (February 2007)

Volume 85, Issue 5, Pages (May 2014)

Terry Behrend, Steven B. Miller, M.D Kidney International

Volume 56, Issue 1, Pages (July 1999)

Prehypertension: is it relevant for nephrologists?

Homocysteine, renal function, and risk of cardiovascular disease

Volume 55, Issue 3, Pages (March 1999)

Volume 57, Issue 1, Pages (January 2000)

Daily nocturnal home hemodialysis

The course of the remnant kidney model in mice

Organ transplantation goes to the movies

Volume 70, Pages S84-S90 (November 2006)

Volume 58, Issue 1, Pages (July 2000)

Volume 72, Issue 7, Pages (October 2007)

Is it the low-protein diet or simply the salt restriction?

Charles A. Herzog Kidney International

Volume 75, Issue 1, Pages (January 2009)

Volume 70, Issue 3, Pages (August 2006)

ANCA comes of age—but with caveats

Volume 70, Issue 5, Pages (September 2006)

Volume 75, Issue 7, Pages (April 2009)

The changing face of childhood nephrotic syndrome

Volume 81, Issue 8, Pages (April 2012)

Dana V. Rizk, David G. Warnock Kidney International

The International Pediatric Peritonitis Registry: Starting to walk

Abby S. Kazley, Kit N. Simpson, Kenneth D. Chavin, Prabhakar Baliga

Prediction in idiopathic membranous nephropathy

Stephen Pastan, J. Michael Soucie, William M. McClellan

Yoshitsugu Kaku, Kaoru Nohara, Sunao Honda Kidney International

Presentation transcript:

Volume 58, Issue 1, Pages 317-324 (July 2000) A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome Kazuo Yoshioka, Yasuo Ohashi, Tadasu Sakai, Hiroshi Ito, Norishige Yoshikawa, Hajime Nakamura, Takakuni Tanizawa, Hiroyoshi Wada, Sunao Maki Kidney International Volume 58, Issue 1, Pages 317-324 (July 2000) DOI: 10.1046/j.1523-1755.2000.00168.x Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 1 Trial profile. Two patients in each group were excluded from the analysis of the relapse rates because they did not achieve remission after allocation. Kidney International 2000 58, 317-324DOI: (10.1046/j.1523-1755.2000.00168.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 2 Relapse rate (A) and cumulative remission rate (B) in mizoribine and placebo groups. Hazards ratio = 0.79; P = 0.13. Kidney International 2000 58, 317-324DOI: (10.1046/j.1523-1755.2000.00168.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 3 Relapse rate (A) and cumulative remission rate (B) in the subgroup of patients aged 10 years or younger at the start of the trial. Hazards ratio = 0.56; P = 0.007. Kidney International 2000 58, 317-324DOI: (10.1046/j.1523-1755.2000.00168.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 4 Distribution of the relapse risk index in the subgroup of patients by age at the start of the trial. Kidney International 2000 58, 317-324DOI: (10.1046/j.1523-1755.2000.00168.x) Copyright © 2000 International Society of Nephrology Terms and Conditions